P450 - REFEEDING SYNDROME IN PATIENTS HOSPITALIZED FOR GASTROINTESTINAL CONDITIONS: INCIDENCE, CLINICAL OUTCOMES, AND ASSOCIATED FACTORS

P450

REFEEDING SYNDROME IN PATIENTS HOSPITALIZED FOR GASTROINTESTINAL CONDITIONS: INCIDENCE, CLINICAL OUTCOMES, AND ASSOCIATED FACTORS

A. Carmel^1,*, E. Parisien-Dubuc¹, L. D'aoust¹, D. C. Daoud¹

¹Centre Hospitalier de l’Université de Montréal, Montréal, Canada

Rationale: Refeeding syndrome (RFS) is a serious complication of nutritional support in malnourished patients, especially those with gastrointestinal (GI) conditions like inflammatory bowel disease (IBD). This study aimed to assess RFS incidence in hospitalized GI patients and identify associated factors.

Methods: We conducted a retrospective cohort study of patients who received nutritional support during hospitalization in the gastroenterology unit at the Centre Hospitalier de l’Université de Montréal between April 2018 and March 2023. Demographic and clinical data were collected. RFS’s incidence was calculated using the ASPEN 2020 criteria and compared between patients with IBD and non-IBD GI conditions. Chi-square and t-tests were used to compare groups. Odds ratios were estimated in univariate models, by controlling for each confounding factor independently.

Results: A total of 195 patients were included (58% female; median age 54 years) consisting of 40 with IBD and 155 without. Parenteral nutrition (p=0.042) and thiamine supplementation (p=0.007) were more frequently used in the IBD group whereas Charlson Comorbidity Index was higher in the non-IBD group (p=<0.001). The RFS incidence was 70% and was similar between IBD and non-IBD patients (p=1). Hospital length of stay, 30- and 60-day mortality, and 30-day readmission rates were similar between patients with and without RFS and patients with or without IBD. Factors associated with RFS included higher baseline potassium (OR=1.8), magnesium (OR=25.7), phosphate (OR=11.2), and leukocyte count (OR=1.2).

Conclusion: In hospitalized GI patients, RFS’s incidence was high and similar in both IBD and non-IBD patients. It wasn’t associated with longer hospital stay, mortality, or readmission. Biochemical markers were linked to RFS, but further studies are needed to confirm their predictive value. 

Disclosure of Interest: A. Carmel: None declared, E. Parisien-Dubuc: None declared, L. D'aoust: None declared, D. C. Daoud Consultant for: Takeda Pharmaceutical and Pendopharm consultant